A clinical and biochemical assessment of etidronate disodium in patients with active rheumatoid arthritis |
| |
| Authors: | Dr. H. A. Bird J. Hill N. G. Sitton J. S. Dixon V. Wright |
| |
| Affiliation: | (1) Clinical Pharmacology Unit, Royal Bath Hospital, Harrogate and University Department of Medicine, General Infirmary at Leeds, Leeds, UK;(2) Clinical Pharmacology Unit, Royal Bath Hospital, Cornwall Road, HG1 2PS Harrogate, North Yorkshire, UK |
| |
| Abstract: | Summary Diphosphonates reduce the rate of bone turnover. They have additional pharmacological properties improving adjuvant arthritis in rats and lowering ESR in this condition. We have evaluated etidronate disodium, a diphosphonate commonly prescribed in the United Kingdom for Paget's disease in patients with rheumatoid arthritis. Apart from an early improvement in articular index, perhaps reflecting anti-inflammatory activity, no significant change occurred in clinical variables or in laboratory indices of  secondline action at a dose of 5 mg/kg/day. |
| |
| Keywords: | Etidronate Rheumatoid Arthritis |
| 本文献已被 SpringerLink 等数据库收录！ |
|
